These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 11540095)

  • 1. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption.
    Yu LX; Lipka E; Crison JR; Amidon GL
    Adv Drug Deliv Rev; 1996 Jun; 19(3):359-76. PubMed ID: 11540095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
    Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
    Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically Based Absorption Models.
    Sjögren E; Thörn H; Tannergren C
    Mol Pharm; 2016 Jun; 13(6):1763-78. PubMed ID: 26926043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.
    Margolskee A; Darwich AS; Pepin X; Pathak SM; Bolger MB; Aarons L; Rostami-Hodjegan A; Angstenberger J; Graf F; Laplanche L; Müller T; Carlert S; Daga P; Murphy D; Tannergren C; Yasin M; Greschat-Schade S; Mück W; Muenster U; van der Mey D; Frank KJ; Lloyd R; Adriaenssen L; Bevernage J; De Zwart L; Swerts D; Tistaert C; Van Den Bergh A; Van Peer A; Beato S; Nguyen-Trung AT; Bennett J; McAllister M; Wong M; Zane P; Ollier C; Vicat P; Kolhmann M; Marker A; Brun P; Mazuir F; Beilles S; Venczel M; Boulenc X; Loos P; Lennernäs H; Abrahamsson B
    Eur J Pharm Sci; 2017 Jan; 96():598-609. PubMed ID: 27671970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based In vitro Models to Predict the Oral Dissolution and Absorption of a Solid Drug Delivery System.
    Li Z; He X
    Curr Drug Metab; 2015; 16(9):777-806. PubMed ID: 26264200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling of drug disposition kinetics in in vitro intestinal absorption cell models.
    Heikkinen AT; Korjamo T; Mönkkönen J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):180-8. PubMed ID: 20030630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review.
    O'Shea JP; Augustijns P; Brandl M; Brayden DJ; Brouwers J; Griffin BT; Holm R; Jacobsen AC; Lennernäs H; Vinarov Z; O'Driscoll CM
    Eur J Pharm Sci; 2022 Mar; 170():106098. PubMed ID: 34954051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paediatric oral biopharmaceutics: key considerations and current challenges.
    Batchelor HK; Fotaki N; Klein S
    Adv Drug Deliv Rev; 2014 Jun; 73():102-26. PubMed ID: 24189013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
    Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopharmaceutic classification of drugs revisited.
    Daousani C; Macheras P
    Eur J Pharm Sci; 2016 Dec; 95():82-87. PubMed ID: 27496048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the impact of physiological and biochemical processes on oral drug bioavailability.
    Agoram B; Woltosz WS; Bolger MB
    Adv Drug Deliv Rev; 2001 Oct; 50 Suppl 1():S41-67. PubMed ID: 11576695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review.
    Guimarães M; Statelova M; Holm R; Reppas C; Symilllides M; Vertzoni M; Fotaki N
    J Pharm Pharmacol; 2019 Apr; 71(4):603-642. PubMed ID: 29971768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ontogeny of oral drug absorption processes in children.
    Mooij MG; de Koning BA; Huijsman ML; de Wildt SN
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1293-303. PubMed ID: 22686526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral biopharmaceutics-current status and identified gaps of understanding.
    Lennernäs H; Abrahamsson P; Langguth B
    Eur J Pharm Sci; 2014 Jun; 57():98. PubMed ID: 24508580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.